Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Companies held a joint conference call and webcast, Wednesday, April 3 at 8:30 AM ET
ACCESS THE WEBCAST REPLAY
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Companies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ET
ACCESS THE WEBCAST HERE
Advancing Two Innovative Platform Technologies
IMMUNE FX™ (IFx™): Personalized Cancer Vaccines Harnessing the Power of the Innate Immune Response
Our IFx technology is designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria and harness the power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.
Bi-Functional Antibody Drug Conjugates (ADCs)
Leveraging our proprietary Delta receptor technology we are developing first-in-class bi-functional antibody drug conjugates (ADCs) that target Myeloid Derived Suppressor Cells (MDSCs) to inhibit their immune suppressing effects of MDSCs on the tumor microenvironment. This may prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies, allowing them to continue working.
Pipeline
Your tooltip content goes here
Your tooltip content goes here
Your tooltip content goes here